A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

NCT05535920 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Hyperkalemia

Interventions

DRUG: LOKELMA 5 GM Powder for Oral Suspension

Sponsor

NephroNet, Inc.

Collaborators

[object Object]